VEGFA and renal cell carcinoma: While chemotherapy is no longer recommended to treat RCC, and sunitinib and sorafenib have since been replaced by newer generation VEGF TKIs as first-line treatment options, miRNAs may modulate treatment efficacy in newer VEGF TKIs as well, and may explain why certain patients’ tumors are more sensitive to treatment compared to others [54].